Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer po...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Joshua P. Schiff, Patrick Cotogno, Allison Feibus, Peter Steinwald, Elisa Ledet, Brian Lewis and Oliver Sartor Tags: Research article Source Type: research